Abstract: Accurate detection of gram-positive bacterial colonies is essential for managing chronic wounds and overcoming delays in healing, as these bacteria can worsen wound conditions and impede ...

An observational study found that infants who had more diverse bacteria in their gut had lower childhood blood pressure, and this protective association was stronger if they were breastfed for at ...

Vancomycin is a common antibiotic used to treat gram-positive bacterial infections. It targets a key building block of the bacterial cell wall called Lipid II, but it can’t reach this lipid in ...

Pneumonia is a disease that burdens the health care system with more than 1.2 million emergency room visits each year and more than 41,000 adult deaths in the United States. Worldwide, more than one ...

Antimicrobial resistance (AMR) is one of the world’s most urgent health challenges, with the WHO’s recent report showing there are “too few antibacterials in the pipeline” and the limited commercial ...

Announcing a new article publication for Zoonoses journal. The prevalence of antimicrobial resistance is increasing among gram-positive bacteria, particularly the resistance of methicillin-resistant ...

Gram-negative bacteria pose a significant threat to global health due to their high resistance to antibiotics compared to that of Gram-positive bacteria. Their formidable defensive capabilities stem ...

ABSTRACT: Introduction: Antimicrobial resistance (AMR) remains a critical global health issue contributing to increased morbidity and mortality. Antimicrobial stewardship (AMS), surveillance, and ...

Background: Due to a lack of studies on the relationship between vancomycin trough concentration and clinical outcomes in pediatric patients, there is insufficient evidence to provide a unified ...

NEW YORK – Diasorin said Saturday that it has received US Food and Drug Administration 510(k) marketing clearance for a syndromic panel to detect and identify the Gram-positive causes of bloodstream ...

Swiss drug maker Roche hit the headlines when it announced that it is advancing the development of its antibiotic zosurabalpin into phase 3 trials. The candidate will “address the challenge of ...